多囊卵巢综合征患者中AMH启动子多态性与血清AMH水平的关联
本研究在多囊卵巢综合征(PCOS)女性中发现新的AMH启动子多态性rs10406324,其次要等位基因G携带者血清AMH水平显著低于非携带者,且在三个PCOS队列及正常排卵女性中均得到验证,提示遗传因素参与AMH水平调控。
要点
- rs10406324次要等位基因G与PCOS患者及正常排卵女性血清AMH水平降低相关。
- 该多态性与卵泡计数及其他临床特征无关。
- 体外分析未显示A与G等位基因启动子活性差异。
核心结论
- rs10406324与血清AMH水平降低相关,提示遗传因素参与AMH表达调控,评估AMH时需考虑遗传背景。
研究设计与样本
- 发现队列655例北欧裔PCOS女性,内部验证队列458例,外部验证队列321例,对照为包含7049例正常排卵女性的AMH全基因组关联研究荟萃分析汇总数据。
- 采用关联分析及计算机模拟分析AMH启动子变异,并用小鼠颗粒细胞系KK1和人颗粒细胞瘤细胞系COV434进行体外功能分析。
主要发现
- rs10406324在三个PCOS队列中均与血清AMH水平显著相关,次要等位基因G携带者log转换后血清AMH水平显著低于非携带者(P=8.58×10⁻⁸、P=1.35×10⁻³、P=1.24×10⁻³)。
- 后续荟萃分析验证该关联(P=3.24×10⁻¹²)。
- rs10406324与卵泡计数及其他临床特征无关。
- 在正常排卵女性中,该变异次要等位基因亦与较低血清AMH水平相关(P=1.04×10⁻⁵)。
- 计算机模拟分析提示转录因子类固醇生成因子1、雌激素相关受体α和糖皮质激素受体与次要等位基因G结合亲和力降低,但体外分析未显示A与G等位基因启动子活性差异。
临床怎么用
- 作者认为评估女性血清AMH水平时应考虑遗传背景,尤其当AMH用作多囊卵巢形态表型标志物时可能有临床意义。
局限性
- 功能分析在小鼠和人颗粒细胞系中使用AMH启动子报告构建体进行,可能限制了对高阶染色质结构影响的评估。
- 外部验证队列和对照队列缺乏卵泡计数是本文的局限。
- 尽管在发现和内部验证PCOS队列中观察到rs10406324与AMH水平的关联独立于卵泡计数,但不能完全排除血清AMH水平效应部分由卵泡计数差异引起。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Do polymorphisms in the anti-Müllerian hormone (AMH) promoter have an effect on AMH levels in patients with polycystic ovary syndrome (PCOS)? SUMMARY ANSWER: We have identified a novel AMH promoter polymorphism rs10406324 that is associated with lower serum AMH levels and is suggested to play a role in the mechanism of regulation of AMH gene expression in women. WHAT IS KNOWN ALREADY: Follicle number is positively correlated with serum AMH levels, reflected by elevated AMH levels in women with PCOS. In addition, it is suggested that AMH production per follicle is higher in women with PCOS than in normo-ovulatory women, implying an altered regulation of AMH in PCOS. STUDY DESIGN, SIZE, DURATION: A discovery cohort of 655 PCOS women of Northern European ancestry and both an internal and external validation PCOS cohort (n = 458 and n = 321, respectively) were included in this study. Summary-level data of an AMH genome-wide association study meta-analysis including 7049 normo-ovulatory women was included as a control cohort. A genetic approach was taken through association analysis and in silico analysis of the associated variants in the AMH promoter. In vitro analysis was performed to investigate the functional mechanisms. PARTICIPANTS/MATERIALS, SETTING, METHODS: All common two-allelic single-nucleotide polymorphisms (SNPs) in the region Chr19:2 245 353-2 250 827 bp (Build 37) were selected for the analysis. Linear regression analyses were performed to determine the association between SNPs in the AMH promoter region and serum AMH levels. For the in silico analysis, the webtools 'HaploReg' v4.1 for ENCODE prediction weight matrices and 'atSNP' were used. In vitro analysis was performed using KK1 cells, a mouse granulosa cell line and COV434 cells, a human granulosa tumor cell line. Cells were transfected with the reference or the variant human AMH promoter reporter construct together with several transcription factors (TFs). Dual-Glo® Luciferase Assay was performed to measure the luciferase activity. MAIN RESULTS AND THE ROLE OF CHANCE: Polymorphism rs10406324 was significantly associated with serum AMH levels in all three PCOS cohorts. Carriers of the minor allele G had significantly lower log-transformed serum AMH levels compared to non-carriers (P = 8.58 × 10-8, P = 1.35 × 10-3 and P = 1.24 × 10-3, respectively). This result was validated in a subsequent meta-analysis (P = 3.24 × 10-12). Interestingly, rs10406324 was not associated with follicle count, nor with other clinical traits. Also, in normo-ovulatory women, the minor allele of this variant was associated with lower serum AMH levels (P = 1.04 × 10-5). These findings suggest that polymorphism rs10406324 plays a role in the regulation of AMH expression, irrespective of clinical background. In silico analysis suggested a decreased binding affinity of the TFs steroidogenenic factor 1, estrogen-related receptor alpha and glucocorticoid receptor to the minor allele G variant, however in vitro analysis did not show a difference in promoter activity between the A and G allele. LIMITATIONS, REASONS FOR CAUTION: Functional analyses were performed in a mouse and a human granulosa cell line using an AMH promoter reporter construct. This may have limited assessment of the impact of the polymorphism on higher order chromatin structures. Human granulosa cells generated from induced pluripotent stem cells, combined with gene editing, may provide a method to elucidate the exact mechanism behind the decrease in serum AMH levels in carriers of the -210 G allele. We acknowledge that the lack of follicle number in the external validation and the control cohort is a limitation of the paper. Although we observed that the association between rs10406324 and AMH levels was independent of follicle number in our discovery and internal validation PCOS cohorts, we cannot fully rule out that the observed effects on serum AMH levels are, in part, caused by differences in follicle number. WIDER IMPLICATIONS OF THE FINDINGS: These results suggest that variations in serum AMH levels are not only caused by differences in follicle number but also by genetic factors. Therefore, the genetic context should be taken into consideration when assessing serum AMH levels in women. This may have clinical consequences when serum AMH levels are used as a marker for the polycystic ovarian morphology phenotype. STUDY FUNDING/COMPETING INTEREST(S): No external funding was used. J.S.E.L. has received consultancy fees from the following companies: Ferring, Roche Diagnostics and Ansh Labs and has received travel reimbursement from Ferring. J.A.V. has received royalties from AMH assays, paid to the institute/lab with no personal financial gain. The other authors declare no competing interests. TRIAL REGISTRATION NUMBER: N/A.
引用
- Moolhuijsen LME, Louwers YV, McLuskey A, et al. Association between an AMH promoter polymorphism and serum AMH levels in PCOS patients. Hum Reprod. 2022. PMID: 35451015. doi:10.1093/humrep/deac082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。